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Simple Summary: The use of animals in research has been the subject of significant public debate and
concern. Some argue that animal experiments are essential to medical progress, while others believe
that this practice is unethical and does not produce results that can be reliably translated to people. A
growing range of modern techniques can replace the use of animals and provide results that are more
relevant to human patients. These include the use of human cells and tissues, and computer-based
methods. Our work aimed to explore the societal benefits of accelerating the replacement of animals
with these new research methods. We found that this approach would benefit animal welfare, public
health and the economy. We also found that the British public is generally in favor of efforts to replace
animals, and that focusing on this area would help to support the British Government’s policy and
economic goals. We suggest that the British Government could greatly expedite the replacement of
animal experiments by appointing a new minister to take responsibility for this transition.
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Abstract: In the context of widespread public and political concern around the use of animals in
research, we sought to examine the scientific, ethical and economic arguments around the replacement
of animals with New Approach Methodologies (NAMs) and to situate this within a regulatory context.
We also analyzed the extent to which animal replacement aligns with British public and policymakers’
priorities and explored global progress towards this outcome. The global context is especially relevant
given the international nature of regulatory guidance on the safety testing of new medicines. We used
a range of evidence to analyze this area, including scientific papers; expert economic analysis; public
opinion polls and the Hansard of the UK Parliament. We found evidence indicating that replacing
animals with NAMs would benefit animal welfare, public health and the economy. The majority of
the British public is in favor of efforts to replace animals and focusing on this area would help to
support the British Government’s current policy priorities. We believe that this evidence underlines
the need for strong action from policymakers to accelerate the transition from animal experiments to
NAMs. The specific measure we suggest is to introduce a new ministerial position to coordinate and
accelerate the replacement of animals with NAMs.
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1. Introduction
We believe that there is an urgent need to modernize medical research. We use this
term to refer to the process of replacing animal experiments with techniques that have
greater direct relevance to human patients. These approaches include the use of advanced
cultures of human cells and tissues, artificial intelligence and organ-on-a-chip technology.
There is a strong and multi-faceted case for this process of modernization. It is likely
to accelerate much-needed medical progress, and would prevent the suffering caused
to animals by breeding them, housing them in laboratories and experimenting on them.
Within Britain, this transformation would help the Government achieve its current policy
priorities and support economic growth. With demonstrable progress taking place around
the world, the British Government has much work to do to ensure that Britain is not left
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behind. Here, we outline the key arguments in favor of modernizing medical research in
this way, and recommend decisive policy action that the British Government should take
to support this process.
2. The Scientific Case for Modernizing Medical Research
The current system of medical research, which relies heavily on animal use, is failing
to deliver sufficient progress for patients. Several thousand diseases affect humans, but
only around 500 have treatments available [1]. One example is Alzheimer’s disease, which
has seen clinical trial failures of more than 99% [2]. A 2019 review concluded that it was
not possible to recommend any animal ‘model’ that could provide a reliable prediction of
the clinical efficacy of potential treatments for Alzheimer’s [2]. One of the key problems
with using animals in disease research is that they often do not naturally suffer from the
illness that is being investigated. This results in efforts to artificially induce some symptoms
of the disease, whether by physical means or genetic modification. Myriad types of GM
animals have been created to investigate general biology, gene functions etc., and also
to generate models of human diseases, including multiple infectious diseases such as
HIV, immune system defects, blood and metabolic disorders, muscular dystrophy, cancer
immunotherapies, and many others [3].
However, genetic modification does little to address the significant differences in
genetic complement and gene expression between different species. These, and other,
biological differences between species contribute to the high rate of failure in terms of
translation to clinical benefit from biomedical research and product safety testing. For
example, over 92% of drugs that show promise in animal tests fail to reach the clinic and
benefit patients [4]. This high rate of attrition is mainly caused by problems with efficacy
and safety that were not predicted by the animal tests.
Modernizing our approach to medical research can not only help to address this
extremely poor translation of research to human benefit, but is arguably, given the human
ethical issues resulting from such poor translation, absolutely essential. New Approach
Methodologies (NAMs) have been defined as ‘new scientific approaches that focus on
human biological processes to investigate disease and potential treatments, using human
cells, tissues, organs and existing data’ [5].They include the use of advanced cultures of
human cells and tissues, artificial intelligence and organ-on-a-chip technology. Since they
are often based specifically on humans, and are therefore not hampered by extrapolating
from one species to another, these methods provide results that have much greater relevance
to patients. NAMs have proved valuable within the context of the COVID-19 pandemic.
For example, Benevolent AI used computational tools to identify existing drugs that could
be repurposed to treat COVID-19. This process selected a drug called baricitinib, which
had anti-viral and anti-inflammatory properties. It is now authorized for the treatment
of patients hospitalized with COVID-19 in the USA, Japan and India [6]. Computerbased analyses and algorithms are also being used to examine changes in gene expression
caused by COVID-19, and by existing drugs, so that they can be matched—enabling
the repurposing of drugs to restore healthy/normal gene expression in patients with
COVID-19 [7].
3. The Ethical Case for Modernizing Medical Research
Separating the scientific and ethical cases for modernizing medical research may now
be an artificial distinction. The ability of medical research to benefit patients is, of course,
an ethical question, and so animal research involves human, as well as animal, ethical
considerations. Governments and other organizations that use public funds to finance
medical research therefore have an ethical duty towards humans to support methods which
are most likely to lead to progress. In the field of safety testing, scientists and regulatory
bodies should use methods that offer the most accurate predictions, to minimize the risk
of harm to people. However, the section below focuses on the more direct ethical issues
around using animals in experiments.
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It has been argued that the practice of animal research involves an inherent contradiction. It relies on the belief that animals are similar enough to humans to make the results
relevant, but that they are different enough to make it morally acceptable to harm them in
the pursuit of human benefit. In fact, there is strong evidence to show the opposite: that
animals are different in all the ways that make extrapolation of data to humans unreliable,
but are so similar in their capacity to experience suffering that this makes a formidable
ethical case to not do animal experiments at all, regardless of any proposed human benefit.
The Animals (Scientific Procedures) Act 1986 (ASPA), which governs animal experiments in
Britain, seeks to minimize suffering as much as possible. However, this idea of humaneness
is difficult to reconcile with the reality of experimenting on animals. In his response to
a recent debate in the UK Parliament about the use of animals in research, the Minister
for Science, Research and Innovation, George Freeman MP stated that ‘the issue of force
feeding—which is a controversial term—was raised. I have checked the reason for that, and
it is about making sure that the correct dose is administered, but again, the point is well
made: we need to make sure that is being done in the most humane and sentient-friendly
way’ [8]. There is an obvious conflict between the principle of treating animals humanely
and the concept of force-feeding them. As well as the ethical problems with the practice
of force-feeding, it also has implications for the results of the experiments, since it causes
stress and slows down gastrointestinal function [9].
Before they undergo any experiments, being in a laboratory environment is likely to
cause suffering to animals. As discussed in a 2017 editorial by Dr Jarrod Bailey, factors
that contribute to the stress and distress of animals in laboratories include a lack of control
over the ‘procedures’ that they are subjected to, being prevented from expressing many
natural behaviors and unnatural light and noise conditions. This has significant adverse
consequences for both science and animal welfare [10]. Within the European Union,
animal experiments are governed by Directive 2010/63/EU, which divides experiments
into four categories of severity: non-recovery, mild, moderate and severe. The examples
provided within Annexe VIII of the Directive illustrate the suffering that can be endured.
Experiments that are likely to be classified as ‘mild’ include short-term restraint in metabolic
cages or solitary caging of some animals. ‘Moderate’ experiments could be withdrawing
food for 48 h in rats or evoking avoidance and escape reactions where the animal cannot
avoid the cause of the stimulus. ‘Severe’ experiments include inescapable electric shock
to produce learned helplessness or forced swim tests with exhaustion as the end-point.
Britain has maintained these severity categories, along with the main substance of the
Directive, post-Brexit. We would suggest that these examples are unlikely to reflect the
lay-person’s understanding of the terms ‘mild’, ‘moderate’ and ‘severe’, since even ‘mild’
experiments can involve significant suffering. It should be remembered that legislation on
animal experiments, such as ASPA, serves to facilitate actions that would often constitute
illegal animal cruelty if performed by an unlicensed member of the public in normal
circumstances.
In Britain, animal experiments are regulated by the Animals in Science Regulation
Unit (ASRU), within the Home Office. Beyond the harms that are legally sanctioned,
ASRU’s own reports detail additional suffering caused by incidents of neglect. Failures
described in the latest edition of the report include mice being left in a cage in an isolator
without appropriate food and water for over two weeks. In another incident, mice were
left in a laminar flow hood without access to food and water over a weekend. A total of
93% of the incidents detailed in this document were self-reported to the regulator. Of the
remaining two incidents, one was discovered during an inspection, and another reported
by a whistleblower [11]. There is no way of knowing how many further incidents may
have taken place without being reported.
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Alongside these specific incidents, we believe that the provisions of ASPA are routinely
being undermined. The law makes it clear that animal experiments should only be licensed
when no non-animal method is available. However, there is significant evidence to suggest
that this important legal requirement is not being adequately enforced. Analysis by Cruelty
Free International found that in 2020 in the UK, 452 skin sensitization tests were carried out
on mice, even though a validated non-animal method is available [12]. In addition, analysis
by Thomas Hartung et al. found evidence of animal tests for ingredients solely used in
cosmetic products, even after the EU-wide ban on this practice [13]. A Parliamentary
Question by Alex Sobel MP revealed that no applications to conduct animal experiments
were refused permission in 2020 [14]. In the European Union, it is estimated that up to threequarters of a million animal tests take place every year in spite of validated alternatives
that have existed for some time [15].
Understanding the process behind license applications makes this less surprising. By
the time a researcher submits a license application to ASRU, it is likely that funding for
the project will have been secured, and it will have received support from the Animal
Welfare Ethical Review Body (AWERB) at the establishment where the work is to take place.
While researchers are supposed to thoroughly consider non-animal methods, there is a
significant lack of knowledge within the scientific community about these. The AWERBs
are not likely to have detailed knowledge of non-animal methods within each specialist
research area. This issue is further highlighted by Judith van Luijk’s work surveying animal
welfare officers in the Netherlands, whose role includes advising on the 3Rs. While all
15 respondents believed they contributed to implementing refinement, only one believed
they contributed to replacement. Over half of the respondents felt that opportunities to
implement the 3Rs were being missed [16]. Within the UK, the ASRU inspectors who grant
the licenses have limited knowledge and little time. In 2018 (the latest figures available)
there were just 22 ASRU inspectors (20.8 full time equivalents) [11]. Analysis of the nontechnical summaries of licenses granted during the first half of 2020 showed that researchers
often failed to engage meaningfully with the question that asked them to explain their
strategy in searching for non-animal alternatives. Analysis by Animal Free Research UK
identified 34 examples of a clear lack of engagement. In the most extreme case, a one-word
answer was provided, and there were many examples of researchers simply listing a few
non-animal methods and stating that these were not suitable, rather than explaining the
in-depth research that should have been carried out to identify non-animal approaches.
Researchers should be provided with practical training in identifying non-animal methods.
One example of this is the free e-learning module that has recently been made available by
the Education and Training Platform for Laboratory Animal Science [17].
It is also important to consider how animal experiments affect the researchers who
carry them out. A survey amongst people carrying out animal experiments in Poland
provided preliminary data on this subject. A total of 72% of the respondents felt an
emotional burden as a result of carrying out animal experiments and 63% felt stress. The
study’s authors suggest one contributing factor may be the need to closely observe animals
and therefore notice the distress they are experiencing, combined with an obligation
to continue with the experiments [18]. The risk of negative mental health impacts on
researchers who carry out animal experiments, as well as the risk of compassion fatigue,
should be seriously considered and presents yet another ethical issue with this practice.
4. The Economic Case for Modernizing Medical Research
While the following discussion focuses on the economic case for a more modern
approach to research, this also has important ethical dimensions. As the world emerges
from the COVID-19 pandemic, policy makers have a duty to facilitate economic recovery,
whilst ensuring that public health receives adequate funding.
Firstly, the economic cost of current public health challenges should be considered.
While many factors exacerbate these challenges, the current reliance on animal research
and slow progress that flows from this should be considered amongst these. A 2014 report
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produced for Alzheimer’s Research UK estimated that dementia costs the UK economy
£23.6 billion, which was predicted to rise to £59.4 billion by 2050. The report also examined
how the economic impact would change if new treatments were found. If an intervention
was produced that delayed the onset of dementia by five years, the cost to the economy
would reduce by 36% (saving over £21 billion that year). However, it is disappointing to
note that this 2014 report modeled its predictions on a new intervention being available by
2020 [19]. Clearly, effective new treatments have not yet materialized, and the difficulty in
extrapolating from animal experiments to the clinic is likely to be one of the factors that
have contributed to this ongoing failure.
The high attrition rate of drugs could also play a role in increasing the cost of providing public healthcare. While many factors contribute to the elevated cost of medicines,
high attrition rates have been amongst the causes cited by the pharmaceutical industry,
although this explanation has been questioned by others [20]. Analysis by Deloitte identified a significant increase between 2020–2021 on the estimated return on investment that
biopharmaceutical companies could expect from their late-stage drug pipelines, but this
still only reached an internal rate of return of seven per cent [21]. More accurate models,
that give a better prediction of whether the drug will be safe and effective for humans,
could help to reduce the current rates of drug failure, and could potentially have a positive
impact in lowering the cost of these new medicines. Ultimately, this could translate into
savings for public healthcare providers, such as the UK’s National Health Service (NHS),
which purchases the drugs.
As well as reducing the cost of public healthcare, human relevant research methods
represent an area where Britain could play a leading role in an emerging industry, which
could contribute to economic growth. A report commissioned by Animal Free Research
UK and produced by the Centre for Economics and Business Research (Cebr) found that
the UK NAMs sector is already making a valuable contribution to the British economy
and this is likely to grow significantly over the coming years. In 2019, the NAMs sector
contributed an estimated £2.3 billion in turnover and £592 million in gross value added
(GVA). The report forecasts that by 2026, the NAMs industry will contribute £2.5 billion
to UK GDP – an increase of 700% since 2017 [22]. It is worth noting that these predictions
did not take account of any future policy interventions. If the British Government were to
support this industry, such as by providing specific grant funding or increased advantage
within the Research and Development (R&D) tax relief system, the potential for growth
would increase further. The economic benefits of NAMs should be considered within the
context of the issue of waste in current research. A 2014 series in the Lancet considered the
issue of research waste. Despite major global investment in biomedical research (US$240
billion in 2010) it acknowledges that a great deal of this fails to produce achievements that
benefit people. While it concedes that some waste is inevitable, it suggests that significant
changes need to be made to tackle avoidable waste [23]. Currently, very little funding is
provided for non-animal research. A 2014 survey found that this was between 0-0.036 per
cent of national science R&D expenditure amongst responding EU member states [24].
5. Public Support for Modernizing Medical Research
Various opinion polls have suggested a high level of public concern around the issue
of animal experiments. A February 2021 YouGov poll, which was commissioned by Animal
Free Research UK, found that 60% of respondents would support the British Government
providing more financial support for developing alternatives to experimenting on animals
in medical research; 68% of respondents would support a policy ending animal experiments
in medical research in the UK and replacing them with non-animal alternatives; and 70%
of respondents would support animal experiments in medical research being phased out
by 2040 [25]. Similarly, a YouGov poll commissioned by Cruelty Free International in
September 2021 found that 65% of respondents wanted to see a binding plan in place for
ending animal testing [26].

Animals 2022, 12, 1173

6 of 12

While both these polls were commissioned by organizations that seek to replace the
use of animals in research and testing, it should be noted that YouGov is independent of
these and has stringent standards on the quality of its research. In addition, the results of
these polls are in line with the government-commissioned 2018 Ipsos MORI poll in which
three quarters of respondents thought that more should be achieved in finding alternatives
to animal experiments [27].
This concern around animal experiments reflects the British public’s wider concerns
around animal welfare. In a recent debate on animal testing in Parliament, a number of
MPs commented on the level of concern amongst their constituents about animal welfare
issues [8]. The current interest in veganism could lead to more people recognizing the rights
of animals and questioning whether it is ethical to harm them in the pursuit of human
benefit. This focus on animals’ fundamental rights clearly differs from the approach of
animal welfare, which accepts the use of animals but seeks to ensure that their suffering is
minimized. The number of vegans in Britain quadrupled between 2014-19 [28]. In a 2014
study, over 89% of respondents mentioned issues relating to animals as one of the factors
that motivated them in adopting a vegan diet [29].
Animal protection groups often emphasize the millions of animals who are used
each year in research—some 200 million globally [30]. While it is vital to highlight the
scale of animal use, it may be worth considering how this might impact on public and
political concern for animals in laboratories. ‘Compassion fade’ is a well-documented
phenomenon, which describes the tendency for compassion to decrease as the number of
victims increases. This results in people being more moved by a single child in need of
help than a group of children. While studies have mainly focused on human victims, a
2013 study examined whether this applied to people’s responses to animal suffering. This
was in the context of environmental threats rather than animals being directly subjected
to harm by people (as in the case of animal experiments). The researchers found that the
‘compassion fade’ phenomenon did persist, but only amongst people who did not consider
themselves to be environmentalists [31]. Given the millions of animals used in experiments,
it is possible that the ‘compassion fade’ phenomenon could reduce public sympathy for
them. Nonetheless, as discussed above, it seems that any sense of ‘compassion fade’ in
relation to individual animals does not prevent the public from supporting more decisive
action from policymakers in replacing animal research.
6. Modernizing Medical Research within the British Policy Context
Modernizing medical research would appear to support the British Government’s
current policy priorities. The Government frequently mentions its ambition to make Britain
a ‘science superpower’, and this has become a regular element of its post-Brexit phraseology.
During the budget announcement in October 2021, for example, Chancellor Rishi Sunak
stated that ‘we are making this country a science and technology superpower’ [32]. While
the Government has repeatedly emphasized its commitment to providing financial support
for R&D, the post-pandemic environment has seen some cooling of these commitments.
The Autumn 2021 Budget and Spending Review, for example, confirmed the commitment
to invest £22 billion in R&D, but this would be by 2026/27 and not the original target date
of 2024/25 [32,33].
The past year has also seen some policy progress in the field of animal welfare. The
2021 Queen’s speech mentioned a commitment to high standards of animal welfare, and a
number of draft Bills have followed on from this [34]. For example, the Animal Welfare
(Kept Animals) Bill, which is currently going through Parliament, contains measures to
tackle puppy smuggling, ban the export of live animals for fattening and slaughter and end
the keeping of primates as pets [35]. Arguably one of the most significant developments
has been the Animal Welfare (Sentience) Bill, which ensures that this concept is enshrined
in British law post-Brexit [36]. While the bill has many shortcomings, such as its limited
mechanisms for ensuring that animal sentience is adequately considered by policymakers,
its existence is undoubtedly a positive step for animal protection. A survey by NFP Synergy
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found animals were the third most popular cause amongst MPs. This was chosen as a
favorite cause by 38% of MPs (behind cancer and children and young people). In fact, the
survey found that animal welfare was the top favorite cause amongst Conservative MPs
(selected by 45%) [37]. The context of a Conservative government in Britain makes this
especially interesting.
However, animals in laboratories have not benefitted from the recent focus on animal welfare. For example, the Government’s May 2021 Action Plan for Animal Welfare
contained just one sentence about animals used in experiments, and this did not offer any
new measures [38]. Clearly, the reasons for this lack of progress will be complex and multifaceted but it is possible that the departmental allocation of different issues plays a role.
Animal welfare is the responsibility of the Department for Environment, Food and Rural
Affairs (Defra), which also deals with wildlife and farmed animals, while the Home Office
is responsible for animals in laboratories. The minister with direct responsibility for this
area has a diverse portfolio that includes countering extremism and forensic science [39]
and has not shown any detailed engagement on the issue of animal experimentation.
Another key barrier to progress is regulatory. International regulations on the development of medicines, such as those produced by the International Council for Harmonization
of Technical Requirements for Pharmaceuticals for Human Use (ICH), generate the clear
expectation that animals should be used in tests [40]. This can contribute to a misconception
amongst the public and policymakers that rigid legal requirements preclude any policy
action to accelerate the replacement of animal experiments with more modern techniques.
However, it is worth noting that these regulations take the form of guidelines rather than
legislation and offer some flexibility for individual regulators to adapt their approach.
Britain’s Medicines and Healthcare products Regulatory Agency (MHRA) has given one
example where it did not require data from animal tests before a new therapy could proceed
to clinical trials. While this case was unusual, it does demonstrate that some divergence
from usual practices is possible [41]. Despite this apparent flexibility, it is worth noting that
regulatory requirements are still an important driver of animal tests and represent a hurdle
which must be addressed.
In addition, the development of the COVID-19 vaccines saw some departure from the
usual linear process in which animal tests had to be completed before human clinical trials.
It was agreed by the International Coalition of Medicines Regulatory Authorities (ICMRA)
that ‘it is not required to demonstrate the efficacy of the SARS-CoV-2 vaccine candidate in
animal challenge models prior to proceeding to [first in human] FIH clinical trials’ [42]. In
March 2020, a COVID-19 vaccine from Moderna Therapeutics was trialed in humans at the
same time as animal tests were carried out [43]. Whilst this does not mean that animal tests
were ‘skipped’, it does demonstrate some flexibility from regulators.
Fundamentally, it should be noted that tests to satisfy regulatory requirements account
for a relatively small proportion of the overall number of experiments. In 2020, only
33% of experimental ‘procedures’ in Great Britain were carried out to satisfy regulatory
requirements. The largest proportion of experiments came under the category of basic
research (53%), for which there is no regulatory requirement for animal use [44].
Taking decisive action to modernize medical research could help the British Government combine its ambitions to make Britain a science superpower and a world leader on
animal welfare.
7. Modernizing Medical Research within a Global Context
Recent years have seen significant global progress in replacing animals with human
relevant techniques.
One of the best-known examples of this is activity by the US Food and Drug Administration (FDA). The agency has produced a series of reports and roadmaps on the subject of
replacing animals in the field of toxicity testing. These are listed in Table 1 below.
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Table 1. Relevant publications by the FDA.
Year

2011

2017

Publication

Significance

Advancing Regulatory Science at FDA [45]

Identifies the need to
modernize toxicology as one
of eight priority areas.
Includes commitment to
develop tools that better
predict patient responses, and
to using computational
methods. However, also
commits to developing new
‘animal models’.

FDA’s Predictive Toxicology Roadmap [46]

Sets out a series of steps to
promote the development of
NAMs and integrate these
into regulatory assessments.
These include training and
improved communication
with drug developers.

2021 Advancing New Alternative Methodologies at FDA [47]

Developed by the Alternative
Methods Working Group,
reports on progress in NAM
development and integration
across the FDA.

The Netherlands has also seen strong progress in this field, although the strategy has
become less specific and time-bound following a change in administration. In 2016, the
country’s Agriculture Minister requested that the Netherlands should become a world
leader in animal-free innovations, and tasked the Netherlands National Committee for
the protection of animals used for scientific purposes (NCad), with developing a phaseout plan. The work undertaken by the committee suggested that some areas of animal
use for regulatory testing could be phased out as early as 2025 [48]. When the Rutte
III administration took office, the Dutch Government moved away from the mention of
specific dates but worked to facilitate collaboration by establishing the Transition Program
for Innovation without the use of animals (TPI). This is a partnership between government,
industry, academia and third sector stakeholders [49].
The TPI has spearheaded valuable collaborative initiatives such as ‘helpathons’, which
won the Lush Prize for training in 2020 [50]. These collaborative workshops bring different
parties together to find new ways to address research questions without the use of animals.
Another important initiative is the Beyond Animal Testing Index (BATI), which aims to
benchmark public research organizations according to their progress in the field of replacing
animal experiments. The initiative looks at different ‘domains’ such as capacity building
and research and development. The system then measures institutions’ actions according
to three pillars (commitments, transparency and performance) [51].
Recent months have seen further global progress in replacing the use of animals.
The Swedish Government, for example, has tasked its 3R Center with looking at what
further measures can be taken to minimize animal experiments. This follows requests from
animal protection groups such as Djurens Rätt to develop a plan for phasing out the use of
animals [52]. In September 2021, the European Parliament voted in favor of a resolution
which called for an action plan to phase out animal experiments [53]. This growing
momentum around a phase-out is also reflected in Britain. Over 100,000 people have
signed a petition calling on the British Government to develop a robust plan for phasing
out animal experiments, and this was discussed during a debate in the UK Parliament on
25 October 2021 [54]. The implementation of a phase-out plan would also allow time for
animal-free methods, such as computer modelling, to be optimized and to ensure that they
were as robust as possible.
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8. Call for a British Government Minister to Focus on Modernizing Medical Research
The transition to modern, animal-free medical research will require a number of different inputs, from large-scale dedicated funding to awareness-raising initiatives amongst
scientists, to education and training. However, the importance of political will to change
this paradigm cannot be overstated. Policy action has the capacity to drive and accelerate
technological development and changes in practice. This principle is noted by Charlotte
E. Blattner when explaining how the EU Cosmetics Directive drove significant innovation
in this area [55]. The Directive banned marketing in the EU of cosmetics that had been
tested on animals or contained animal-tested ingredients, as well as banning the practice
of testing cosmetics on animals [56]. A 2021 article by Barthe et al. outlines the many
in vitro and ex vivo methods that have been developed for the safety testing of cosmetics,
including 3D models using human skin equivalent [57]. It should, of course, be noted that
the Cosmetics Directive is currently being undermined by the requirements for animal tests
under chemicals legislation, even for substances only used in cosmetics. However, this
does not alter the technological progress that has come about as a result of the Directive. It
is also worth noting the recent decision from the European Court of Justice which upheld
that under REACH, animal testing must only be used as a last resort [58].
As discussed above, the implementation of concrete plans and targets by policymakers
will be vital to accelerating the replacement of animals. However, the success of these will
depend on policymakers’ commitment and interest in implementing them. In 2015, Innovate UK and a number of other UK bodies published A non-animal technologies roadmap for
the UK. This contained a number of constructive recommendations, such as fostering collaboration between academia and industry, promoting the UK NAMs industry internationally
to drive economic growth, and establishing an advisory board to drive implementation
of the Roadmap [59]. Despite these recommendations, we are not aware that they have
translated into any concrete policy action. This illustrates the pitfalls that progressive
plans and policy documents can face if there is no accountability for their implementation
and progress.
A measure that would drive concrete progress in this area would be establishing
a new ministerial position within the British Government to accelerate the transition to
human relevant science. This new Minister for Human Relevant Science could undertake
key activities needed to drive change such as spearheading a declaration about the need
to modernize medical research, overseeing the production of a roadmap and workplans
setting out how the transition to animal-free science will take place, and taking responsibility for ensuring that these are successfully implemented. A priority area of focus
would be ensuring cooperation between industry and regulators and helping to coordinate international collaboration on areas such as updating pharmaceutical regulations to
facilitate the use of non-animal methods. Above all, they would act as a champion for
animal-free science.
The British Government has already created ministerial roles to ensure progress on
key priorities. Nadhim Zahawi, for example, was appointed as the minister for COVID19 vaccine delivery. While the success of the program depended on vast, multi-faceted
cooperation, establishing a dedicated ministerial role helped to highlight this as a key
priority for the British Government. Similarly, it has been reported that the Government
is considering establishing a new ministerial position to tackle the waiting lists for NHS
medical treatment caused by the COVID-19 pandemic. Again, this would signal clear
government prioritization and focus [60]. Appointing a Minister for Human Relevant
Science would send a clear signal that Britain is serious about modernizing medical research
for the benefit of animals and people. It is also worth noting the plans that are currently
underway to appoint a Patient Safety Commissioner, following a recommendation from
the Independent Medicines and Medical Devices Safety Review [61]. While modernizing
medical research would bring obvious benefits for patient safety, appointing a dedicated
Commissioner for Human Relevant Science could also help to accelerate this vital transition.
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9. Conclusions
There is a powerful case for modernizing medical research by replacing animals
with human relevant techniques. This approach will provide the best possible chance of
accelerating progress in tackling the major public health challenges that have a terrible
impact on patients and place strain on public healthcare systems, providing better results
for people, more quickly. This transformation would help to spare animals from being
subjected to experiments that inherently involve suffering. Engaging with the NAMs sector
also provides significant economic opportunities. Within a British context, transforming
research in this way would align with the public and policymakers’ priorities and help to
place Britain at the forefront of the global shift towards animal-free research. The evidence
in favor of modernizing medical research is becoming increasingly difficult to ignore, and
policymakers should embrace this more ethical and future-focused approach to research.
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